Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →J&J announces definitive agreement to acquire Belgium-based Tibotec-Virco for ~$320M cash and debt, citing antiviral pipeline expansion as primary rationale.
HIV i-Base highlighted TMC114 and TMC125 as the strategic prize, with Tibotec's CSO emphasizing the deal would provide 'long-term financial stability' to…
J&J's own retrospective frames Tibotec as the foundation of its later HIV (Prezista, Intelence), TB (Sirturo) and HCV (Olysio) franchises — the highest-ROI…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Johnson & Johnson acquired Belgium-based Tibotec-Virco, an HIV and antiviral biopharmaceutical company, for approximately $320 million in cash and assumed debt; the deal was announced in March 2002 and completed on April 18, 2002. The acquisition expanded J&J's antiviral R&D and seeded what became its HIV franchise, and the business was renamed Janssen Therapeutics in 2011.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Tibotec-Virco NV (this deal) | 2002 | $320M | — |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2002 deals · Johnson & Johnson deals